A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 334 participants.
Also called NCT02988973
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 334 participants
- Sponsor
- Registry
-
NCT02988973
-
- Other papers using this trial's data
- Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02988973. Randomized; no masking; primary purpose treatment. Start 2017-01-12 (actual); primary completion 2019-09-13 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- roxadustat
- Intervention (Drug)
- DA
- Lead sponsor
- Astellas Pharma Inc
- Collaborator
- Kyntra Bio
Record details
- Record id
cardio:ct-nct02988973- Content hash
735f479f2b46d4c97880efa5f2987cb7ceed0795cf9fbce365c300a864666c11